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on behalf of the GetReal methods review groupIndividual participant data (IPD) meta-analysis is an increasingly used approach for synthesizing and
investigating treatment effect estimates. Over the past few years, numerous methods for conducting an
IPDmeta-analysis (IPD-MA) have been proposed, oftenmaking different assumptions andmodeling choices
while addressing a similar research question. We conducted a literature review to provide an overview of
methods for performing an IPD-MA using evidence from clinical trials or non-randomized studies when
investigating treatment efﬁcacy. With this review, we aim to assist researchers in choosing the appropriate
methods and provide recommendations on their implementation when planning and conducting an
IPD-MA. © 2015 The Authors. Research Synthesis Methods published by John Wiley & Sons, Ltd.
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cross-design1. Introduction
The evaluation of a novel drug or intervention typically involves a series of randomized clinical trials (RCTs) where
its safety and efﬁcacy are extensively tested. Because trials are often relatively small and typically exhibit
differences in study design, selection of subjects, studied outcome(s), dosage, choice of comparator intervention,
and quality of the conducted research, conﬂicting evidence occasionally arises. As a consequence, systematic
reviews have become an important tool to summarize the evidence from these trials and to generalize their
conclusions beyond their speciﬁc settings.
Over the past few decades, several methods have been developed to quantify the results of a systematic
review. Most of these methods adopt a meta-analytical rationale and pool the results from individual studies by
accounting for various forms of uncertainty (Sutton et al., 2009; Sutton and Higgins, 2008). Hereby, group-level
summary statistics (aggregate data (AD)) that quantify the treatments’ relative efﬁcacy or safety are retrieved from
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4Unfortunately, when synthesizing published AD, even rigorously conducted meta-analyses can be of limited
value. In particular, when there is substantial heterogeneity in estimates of relative treatment effect, a weighted
average may no longer be informative in medical care. In such situations, it is important to identify whether
treatment effects vary across clinical subgroups because of effect modiﬁcation. Although published AD can be
used for exploring modiﬁers of treatment effect, such approach lacks power when published summary statistics
(e.g., mean age) do not vary much across studies. More importantly, the use of published AD to investigate effect
modiﬁcation is prone to bias because it cannot properly take subject-level characteristics into account. This bias is
also known as the “ecological fallacy” (Berlin et al., 2002). Additional problems arise when AD are not available,
poorly reported, derived and presented differently across studies (for example, odds ratio versus relative risk),
and more likely to be reported (and in greater detail) when statistically or clinically signiﬁcant (Riley et al.,
2010). For this reason, investigators increasingly embark into an individual participant data meta-analysis (IPD-MA)
(Riley et al., 2010; Thompson, 2009; Stewart and Tierney, 2002). These meta-analyses include the raw data from
each relevant study that is (ideally) identiﬁed through a systematic review. By securing IPD of individual trials, it
becomes possible to disentangle subject-level and study-level sources of heterogeneity in treatment effect
(van Walraven, 2010; Michiels et al., 2005; Lyman and Kuderer, 2005). This, in turn, may help to explore effect
modiﬁcation (Simmonds and Higgins, 2007; Stewart and Tierney, 2002) and to consistently adjust for confounding
variables (i.e., for differences in baseline characteristics across different treatment arms). Access to IPD may also
help to improve data quality (Lyman and Kuderer, 2005; Stewart and Tierney, 2002; Lau et al., 1998), to standardize
deﬁnitions and analyses (van Walraven, 2010; Lyman and Kuderer, 2005), to obtain complete follow-up data on all
randomized participants (Clarke and Stewart, 1994), to combine studies with different follow-up times (Sud and
Douketis, 2009; Lyman and Kuderer, 2005; Stewart and Tierney, 2002; Lau et al., 1998), to analyzemultiple outcomes
(Bujkiewicz et al., 2014; Li and Meredith, 2003), to investigate long-term outcomes (Stewart and Tierney, 2002), and
to investigate rare exposures.
Because limited guidance currently exists on dealing with challenges that are speciﬁc to IPD-MA, we embarked
on a literature review to identify state-of-the-art methods and to provide recommendations on their
implementation. This review aims to help systematic reviewers with a limited background in medical statistics
in identifying relevant methods for their IPD-MA.2. Methods
2.1. Information sources
We conducted a literature review to identify scientiﬁc, peer-reviewed articles that focus on methods for IPD-MA to
investigate treatment efﬁcacy using evidence from clinical trials or non-randomized studies. Medline and Embase
databases were queried using a combination of relevant keywords in the Pubmed and Ovid platform (Supporting
Information 2). The corresponding search strategy was independently reviewed by two librarians. They concluded
that the search strategy did not meaningfully improve when medical subject headings terms were included or
search terms were truncated. A selected set of key journals was also hand-searched: the Journal of Research
Synthesis Methods and the Journal of the Royal Statistical Society (series A, B, and C). Databases were searched
from the earliest date until January 27, 2014. Finally, a last attempt to identify missed key articles was made by
contacting key researchers in the ﬁeld and performing cross-reference checks. Here, relevant hits were added until
March 1, 2015.
Because the search for IPD methods was limited to medical and natural science databases, this review is not
intended to be comprehensive. It is, for instance, well known that several IPD-MA methods have been developed
in the ﬁeld of social sciences. In general, the concepts of meta-analysis are universally applicable across different
scientiﬁc domains, whereas the nature of the data may require tailoring of statistical methods. As a consequence,
a more extensive search strategy is unlikely to add relevant variations in the identiﬁed methods and may fail to
yield any new insights. This effect is known as theoretical saturation (Lilford et al., 2001).
2.2. Eligibility criteria
Articles were considered eligible for inclusion if they were written in English and addressed issues related to
IPD-MA in intervention research. Key IPD-MA issues were deﬁned as statistical models, software routines,
simulation studies, empirical comparisons, didactic examples, and best practice guidelines. Articles were excluded
when IPD-MA methods were applied to address solely a substantive clinical question, without a methodological
focus. Articles for which no full text was available were also excluded.
2.3. Search results
A ﬂowchart of the articles identiﬁed from our search is presented in Figure 1. A total of 3360 unique records
were identiﬁed using the search strategy and were deemed eligible for title screening. Out of these, 3206
records were excluded because they did not have amethodological focus or did not correspond to a peer-reviewed© 2015 The Authors. Research Synthesis Methods published by John Wiley & Sons, Ltd. Res. Syn. Meth. 2015, 6 293–309
Figure 1. Flow diagram of selected studies.
T. P. A. DEBRAY ET AL.article (e.g., conference poster). From the remaining 154 articles, another 16 records were excluded because of
missing full text or non-English language. Finally, when assessing full text, 16 records were added after cross-
reference checks, and one article was removed because it did not adhere to inclusion criteria. A total of 153 articles
were included in the review (Supporting Information 4); a complete list of the included articles can be accessed
online at https://www.zotero.org/groups/wp4_-_ipd_meta-analysis.2
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53. Results
3.1. Conceptual issues
The IPD from a single RCT are often analyzed using regression models where the observed outcome is modeled as
a function of the subjects’ undergone treatment (and, in many cases, other covariates of interest). The intercept
term of these models then represents the study effect (e.g., baseline risk), whereas their regression coefﬁcient
represents the treatment effect. Regression models have two major advantages: First, their implementation is
possible for numerous outcome types (e.g., continuous, binary, and time-to-event), and second, their estimated
coefﬁcients can be interpreted in a fairly straightforward manner. Unfortunately, the implementation of traditional
regression models becomes challenging when a trial consists of multiple centers or when multiple trials need to
be analyzed (as in an IPD-MA). In those situations, regression models need to account for clustering of subjects
within trials (or within centers) by allowing each trial (or center) to have their “own” study and treatment effect.
This approach becomes infeasible when individual trials (or centers) are relatively small. Moreover, corresponding
regression models no longer yield an overall estimate of relative treatment effect, casting doubt about whether
and under what circumstances a certain intervention is advantageous.© 2015 The Authors. Research Synthesis Methods published by John Wiley & Sons, Ltd. Res. Syn. Meth. 2015, 6 293–309
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6Meta-analysis attempts to overcome these issues by pooling relative treatment effects from multiple trials or
centers (henceforth studies) and by borrowing information across these studies during the process. Over the past
few decades, two alternate approaches have been proposed for conducting an IPD-MA (Stewart et al., 2012; Riley
et al., 2010). The most common and conceptually least complicated approach is the so-called two-stage approach.
In this approach, the IPD are ﬁrst analyzed separately in each study to produce study-speciﬁc estimates of relative
treatment effect (and possible treatment-covariate interactions). A combined estimate is then obtained in the
second step by calculating a weighted average (e.g., inverse error-variance-based) of the individual estimates.
Hereby, one may assume that all studies share a common treatment effect and that differences between
estimates from the included studies solely arise because of sampling variation (ﬁxed effects meta-analysis).
Alternatively, it is possible to allow for heterogeneous treatment effects by incorporating variation between
studies and performing a random effects meta-analysis.
In the so-called one-stage approach, the IPD from all studies are analyzed simultaneously by adopting a single
statistical model that fully accounts (random effects meta-analysis), partially accounts (mixed effects meta-
analysis), or does not account (ﬁxed effects meta-analysis) for heterogeneity across studies. These single-stage
models are more commonly known as multilevel or hierarchical models (Simmonds et al., 2005). The
implementation of some common one-stage and two-stage meta-analysis model is illustrated in Supporting
Information 3.
It is conventionally believed that the one-stage and two-stage approaches yield similar estimates of treatment
effects (Stewart et al., 2012; Koopman et al., 2008b; Tudur Smith and Williamson, 2007; Steinberg et al., 1997).
Indeed, it has been shown that under certain conditions, the one-stage and two-stage approaches may lead to
equivalent results (Lyman and Kuderer, 2005; Mathew and Nordström, 2010), particularly when interest lies in
estimating a single treatment effect estimate. The two-stage approach offers several advantages favoring its
implementation in the medical literature. In particular, the two-stage approach is conceptually more intuitive
and therefore requires less statistical expertise when conducting or interpreting an IPD-MA (Stewart et al., 2012;
Koopman et al., 2007). Furthermore, because the two-stage approach analyzes each study separately, study-
speciﬁc estimates are not inﬂuenced by external information. This discrepancy may, for instance, become relevant
when effect modiﬁcation varies across studies and corresponding associations do not follow a well-deﬁned
distribution (Piepho et al., 2012).
Unfortunately, the two-stage approach is known to have little power for detecting nonlinear associations
between continuous exposures and the outcome(s) of interest and for detecting treatment-covariate interactions
(Simmonds and Higgins, 2007; Simmonds et al., 2005; Tudur Smith et al., 2005b; Schmid et al., 2004). In addition,
the two-stage approach may lead to bias in pooled effects, standard errors, between-study heterogeneity, and
correlation between random effects when few studies or few participants (or events) per study are available
(Debray et al., 2013; Stijnen et al., 2010; Tobías et al., 2004), when statistical models cannot fully account for
follow-up times (Poppe et al., 2011; Lyman and Kuderer, 2005; Duchateau et al., 2001; Buyse and Piedbois,
1996) or for the time between recurrent events (Haines and Hill, 2011; Jones et al., 2009). Although methodology
to overcome some of these limitations has been described (Stijnen et al., 2010), the one-stage approach offers the
highest degree of ﬂexibility for making necessary assumptions and is therefore often considered to be superior.
The two-stage approach can, however, still be useful to explore the available data, to present intermediate results
or to identify key challenges when designing a one-stage meta-analytical model (Stewart et al., 2012).
Although IPD-MA is often considered as gold standard, their implementation is no panacea against the
limitations of meta-analyses that are solely based on published AD. In particular, meta-analysis of raw data may
still be difﬁcult when randomization or follow-up procedures vary, when studies have measured different
covariates or when relevant descriptions of samples, settings, and treatments are not available for every study
included in the meta-analysis (Burdett and Stewart, 2002). Furthermore, IPD-MA may become prone to bias when
IPD are only sought for a speciﬁc subset of studies (e.g., studies conducted by contacts or friends in the research
ﬁeld) or when the availability of IPD is related to study results (Ahmed et al., 2012).
Several recommendations have been made to accommodate for these potential sources of bias (Ahmed et al.,
2012; Stewart and Tierney, 2002). First of all, meta-analyses should be based on studies that are identiﬁed through
a systematic review. Secondly, clinicians from the ﬁeld should actively be involved as they may help to identify
whether important studies may have been missed (Clarke and Godwin, 1998), to collect additional follow-up data
where relevant and to resolve inconsistencies between different data sources. Finally, researchers should seek IPD
for all relevant studies identiﬁed and collect AD for studies where IPD could not be obtained. Methods for
combining IPD and AD are discussed in Section 3.5.
3.2. Statistical models to estimate an overall summary of treatment effect
In the succeeding texts, we describe the common methodology of one-stage IPD-MA models. These hierarchical
models can be viewed as a direct extension of traditional regression models and are also known as generalized
linear mixed models (GLMMs). In contrast to traditional regression models, hierarchical regression models allow
coefﬁcients to follow a certain distribution. For instance, GLMMs may specify that the relative treatment effect
between two speciﬁc interventions varies across studies according to a normal distribution. The mean of this© 2015 The Authors. Research Synthesis Methods published by John Wiley & Sons, Ltd. Res. Syn. Meth. 2015, 6 293–309
T. P. A. DEBRAY ET AL.distribution then simply represents the “average” treatment effect between the two interventions, and its variance
indicates the degree of between-study heterogeneity in treatment effect.
Consider an IPD-MA of i=1,…,M independent studies with k=1,…,Ni subjects each. Let xik be a dummy variable
that indicates treatment group (treatment or control) of subject k in study i. We denote the corresponding outcome
as yik. This outcome can be continuous, binary, ordinal, count, and so on. The GLMM can then be stated as follows:
g E yikð Þð Þ ¼ αi þ βixik (1)
In this model, E(yik) denotes the expected value of yik, the parameter αi represents the study effect (e.g., baseline
risk), and the parameter βi represents the treatment effect. The link function gmay take different forms depending
on the type of outcome data. A detailed overview of possible implementations is discussed in Section 3.4 and also
illustrated in Table 1.
When specifying the study effects in model (1), each αi may be taken as ﬁxed effects (estimated separately in
each study), as a common effect (so αi= α for all studies) or as random effects (αi is drawn from a certain
distribution). Researchers typically allow for heterogeneous study effects by estimating a separate intercept αi
in each study (Abo-Zaid et al., 2013; Higgins et al., 2001; Thompson et al., 2001; Turner et al., 2000) or by specifying
a random-effects distribution on α (Broström and Holmberg, 2011; Simmonds and Higgins, 2007; Goldstein et al.,
2002; Thompson et al., 2001; Turner et al., 2000). A random-effects distribution may also be speciﬁed for βi when
heterogeneity in treatment effects across studies is plausible (Abo-Zaid et al., 2013; Bowden et al., 2011; Katsahian
et al., 2008; Goldstein et al., 2002; Higgins et al., 2001; Thompson et al., 2001). It is conventional and
computationally efﬁcient to assume normal distributions for the random effects (Sutton and Higgins, 2008;
Thompson et al., 2001). Other distributions are also possible (Broström and Holmberg, 2011; Thompson et al.,
2001) but often require more computational power and occasionally lead to convergence issues.Table 1. Basic statistical models for estimating overall treatment effect
Outcome type Model type Basic statistical model –
Continuous GLMM yik ∼ N μik ; σ
2
i
 
or N μik ; σ
2ð Þ
μik ¼ αi þ βixik
(L1)
Binary GLMM yik ∼ Bernoulli pikð Þ
logit pikð Þ ¼ αi þ βixik
(L2)
Ordinal GLMM yijk ∼ Bernoulli qijk
 
logit qijk
  ¼ αi þ ζ j þ βixik
(L3a)
GLMM yijk ∼ Bernoulli qijk
 
logit qijk
  ¼ αij þ βixik
(L3b)
Count GLMM yik ∼ Poisson μikð Þ
ln μikð Þ ¼ αi þ βixik
(L4)
Time-to-event Cox PH hik tð Þ ¼ hi0 tð Þ exp βixikð Þ (L5a)
Cox PH hik tð Þ ¼ h0 tð Þ exp αi þ βixikð Þ
where αi ∼ N 0; σ2ð Þ
or exp αið Þ ∼ σ2Γ σ2ð Þ
(L5b)
Cox PH hik tð Þ ¼ hi0 tð Þ exp αi þ βixikð Þ
with ∑αi ¼ 0
(L5c)
GLMM yijk ∼ Poisson μijk
 
ln μijk
 
¼ αi þ βixik þ λj þ ln tijk
 
(L5d)
GLMM, generalized linear mixed model; PH, proportional hazards.
Overview of statistical models for different outcome types. Each model is discussed in Section 3.4.
© 2015 The Authors. Research Synthesis Methods published by John Wiley & Sons, Ltd. Res. Syn. Meth. 2015, 6 293–309
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8For instance, consider an IPD-MA with a binary outcome where study effects and treatment effects differ across
studies. The following GLMM could then be speciﬁed to estimate an overall treatment effect that is adjusted for
the presence of between-study heterogeneity:
yik ∼ Bernoulli pikð Þ
logit pikð Þ ¼ αi þ βixik
βi ∼ N μ; τð Þ
:
In this model, the pooled treatment effect (i.e., the “average” treatment effect across studies) is given by μ, and
the degree of between-study heterogeneity in treatment effect is given by τ. Because the study effects are
estimated separately in each study, there is no pooled study effect.
3.3. Statistical models to investigate heterogeneity in treatment effect across and within studies
In the previous section, we described common methods to produce an overall summary of treatment effect. These
methods make little or no attempt to explain or investigate differences between study results (heterogeneity)
across studies or to identify subgroup effects (Fisher et al., 2011; Sutton and Higgins, 2008; Simmonds and Higgins,
2007). There has been increasing interest in using meta-analysis to go beyond estimating only the overall
treatment effect. As a consequence, meta-analyses increasingly attempt to identify modiﬁers of treatment effect
by exploring the presence of interaction effects.
Traditional approaches such as meta-regression and subgroup analysis investigate the presence of trial-level
interaction, that is, interaction between treatment status and a speciﬁc study-level covariate. This covariate may
represent a certain study characteristic (such as level of blinding) or a summarized subject-level characteristic
(such as mean age) (Fisher et al., 2011; Sutton et al., 2008; Tudur Smith et al., 2005b; Li and Meredith, 2003;
Yamaguchi et al., 2002). For instance, Berlin et al. (2002) used meta-regression to identify whether anti-lymphocyte
antibody induction therapy is more beneﬁcial in patients with elevated panel reactive antibodies (PRA). Hereto,
they determined the percent of patients with elevated PRA within each study and estimated their association with
the corresponding treatment’s effect size (Berlin et al., 2002).
Although trial-level interactions may indicate the presence of effect modiﬁcation, it has been demonstrated
that such interactions have low statistical power for identifying modiﬁers of treatment effect and may lead to
ecological (aggregation) bias. In particular, associations between aggregated values may not be representative
for individual subjects (Lambert et al., 2002). In the example of induction, meta-regression failed to identify effect
modiﬁcation by PRA because the level of beneﬁt within PRA category changed across studies. A remedy against
this pitfall is to use IPD and to investigate the presence of subject-level interaction (rather than trial-level
interaction). This can be achieved by specifying an interaction term between treatment status and subject-level
covariate in model (1). Details on how to do this in one-stage and two-stage approaches are provided in
Supporting Information 3. The inclusion of interaction terms may also help to adjust for baseline imbalances
despite randomization (Higgins et al., 2001) and to increase the precision of treatment effect estimates (by
including a strong prognostic factor). Estimated interaction terms must, however, be interpreted with care as they
describe a mixture of trial-level and subject-level interactions (Higgins et al., 2001). For this reason, when a
modiﬁer of interest has sufﬁcient variation within and across studies, researchers sometimes specify two (instead
of one) interaction terms: one interaction between treatment status and the study-speciﬁc mean of the covariate
(i.e., the values that would be used in meta-regression) and one interaction between treatment status and the
study-centered covariate values (Donegan et al., 2012; Fisher et al., 2011). In this manner, it becomes possible
to quantify the presence of ecological bias.
Individual participant data meta-analysis often assume common effects for interaction terms to restrict model
complexity and facilitate estimation (Crowther et al., 2012; Teramukai et al., 2004). It is, however, possible that
interaction terms are actually heterogeneous across studies. For this reason, some researchers propose to estimate
subject-level interactions in isolation (“meta-analysis of interaction estimates”). This can be achieved by adopting a
two-stage approach where interaction effects are estimated separately within each study and then pooled in the
second stage of the IPD-MA (Fisher et al., 2011; Simmonds and Higgins, 2007). Alternatively, it is possible to adopt
a one-stage approach by assuming random-effects distributions for the interaction effects (Simmonds and
Higgins, 2007; Schmid et al., 2004). The latter strategy has been demonstrated to have the greatest power and
ﬂexibility, even when few studies are available, and is therefore generally recommended (Katsahian et al., 2008;
Simmonds and Higgins, 2007). Finally, researchers may also attempt to model nonlinear interactions, for example,
by using fractional polynomials (Royston and Sauerbrei, 2004), to model two-way interactions between treatment
and study-level covariates or even to model three-way interactions between treatment, subject-level covariates,
and study-level covariates.
It is important to realize that practical implementation of IPD-MA with interaction terms requires careful
thought, as the range of possible analyses (i.e., options for treating the unknown parameters) could easily lead
to over-ﬁtting and data-dredging. This problem becomes even more apparent when multiple study-level and© 2015 The Authors. Research Synthesis Methods published by John Wiley & Sons, Ltd. Res. Syn. Meth. 2015, 6 293–309
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9subject-level covariates are available and IPD are limited. For this reason, it is recommended to pre-specify
statistical models in a study protocol before collecting or analyzing the IPD (Higgins et al., 2001).
3.4. Modeling of speciﬁc types of outcomes
In the succeeding texts, we describe common statistical models for analyzing speciﬁc types of outcomes and
describe typical estimation procedures. An overview is provided in Table 1.
3.4.1. Continuous. Continuous outcome data are typically modeled using an identity link function (L1). In this
model, βi indicates the absolute change in outcome due to treatment for patients from the i
th study. If the
outcome of interest represents a change from baseline (e.g., a change in depression score since inclusion by
the trial), it is appropriate to adjust for baseline responses. Further discussion can be found in Supporting
Information 3 and (Riley et al., 2013; Goldstein et al., 2002; Higgins et al., 2001; Thompson et al., 2001; Goldstein
et al., 2000).
3.4.2. Binary. When modeling a binary outcome, it is common to use a logit link function (L2). In this model, exp
(βi) represents the odds ratio for the treatment effect in the i
th study. If βi is assumed as a common effect (βi= β for
all studies) or as a random effect (e.g., βi∼N(β, τ
2)), then exp(β) represents the odds ratio for the overall treatment
effect. Examples are provided by (Thomas et al., 2014; Debray et al., 2013; Stijnen et al., 2010; Sutton et al., 2008;
Thompson et al., 2001; Wakeﬁeld and Salway, 2001; Turner et al., 2000).
3.4.3. Ordinal. The logistic model can easily be extended to account for ordinal outcome-type data by relating to
the proportional odds model (Thompson et al., 2001; Whitehead et al., 2001). Let qijk denote the probability of
subject k in study i having a response in category j or below. Hereby, it is assumed that the categories are ordered
in terms of desirability, thus, lower categories are better. The proportional odds model is described in (L3a), where
the parameter ζ j represents the log odds ratios for each category cutoff. This model assumes that there is a
common treatment effect βi and a common study effect αi within each treatment group. It is possible to relax
these assumptions by allowing study effects to vary across different treatment groups (L3b). When the assumption
of proportional odds is violated, generalized ordered models or partial proportional models may be used instead
of the proportional odds model.
3.4.4. Count. Denote yik as the number of events for subject i in study k. A straightforward one-stage approach
may adopt a Poisson distribution with a log-link (L4). Several extensions have been described that for instance,
allow for data with many zeros by introducing a discrete point mass (hierarchical zero-inﬂated Poisson regression)
(Lee et al., 2006; Yau and Lee, 2001; Hall, 2000).
3.4.5. Time-to-event. Let tik denote the observed time (either censoring time or event time) for subject k in study
i. The outcome yik then represents an indicator that the time corresponds to an event (yik=1) or a censoring time
(yik= 0). Common multilevel survival models distinguish between heterogeneity in baseline hazard (e.g., due to
differences in incidence of the event between studies given the same treatment) and heterogeneity in relative
treatment effect (e.g., due to differences in treatment effect size) (Michiels et al., 2005).
The hierarchical Cox proportional hazards regression model is a popular approach for analyzing survival data
from multiple studies as it requires no assumptions regarding the distribution of the baseline hazard rate (Michiels
et al., 2005; Tudur Smith et al., 2005a,2005b; Sargent, 1998). This model may account for heterogeneity in baseline
hazard (that is, the presence of study effects) by stratifying the baseline hazard by study (L5a). Examples of this
strategy are provided in (Crowther et al., 2012; Bowden et al., 2011; Thompson et al., 2010; Katsahian et al.,
2008; Tudur Smith and Williamson, 2007; Michiels et al., 2005; Tudur Smith et al., 2005a,2005b; Trikalinos and
Ioannidis, 2001). Because L5a does not yield a direct estimate of the trial effect, more advanced approaches
attempt to investigate this heterogeneity by introducing a frailty term αi. It is then assumed that the hazards
within each study are proportional to the same common baseline hazard function (L5b). Examples of this second
strategy are provided in (Crowther et al., 2012; Bowden et al., 2011; Katsahian et al., 2008; Rondeau et al., 2008;
Tudur Smith et al., 2005a; Yamaguchi et al., 2002; Vaida and Xu, 2000; Yamaguchi and Ohashi, 1999; Sargent,
1998; Yau and McGilchrist, 1998). Alternatively, it may be assumed that the baseline hazard functions for each
study have the same shape but may have different magnitudes (L5c) (Michiels et al., 2005). Further extensions
of these models may consider time-dependent frailties (Yau and McGilchrist, 1998).
Similar to other outcome-type data, heterogeneity in treatment effect can be investigated by specifying a
random effects distribution, for example, βi∼N(β, τ
2) or βi= β + bi where bi ∼N(0, τ
2) (Rondeau et al., 2008; Michiels
et al., 2005; Tudur Smith et al., 2005a; Yamaguchi et al., 2002; Vaida and Xu, 2000; Yamaguchi and Ohashi, 1999). In
general, the use of stratiﬁed models with random treatment effects (that is, L5a or L5c using normally distributed
frailty terms) has been recommended as these models maintain the within-study structure while allowing for
heterogeneity in study and treatment effects (Tudur Smith et al., 2005a; Yamaguchi et al., 2002).© 2015 The Authors. Research Synthesis Methods published by John Wiley & Sons, Ltd. Res. Syn. Meth. 2015, 6 293–309
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time-to-event outcome data (Crowther et al., 2012; Fisher et al., 2011; Thompson et al., 2010; Sargent, 1998). For
this reason, researchers may choose to approximate the baseline hazard function by deﬁning a piece-wise
constant or a spline function (Royston and Parmar, 2002; Vaida and Xu, 2000; Sargent, 1998; Yau and McGilchrist,
1998). Alternatively, it has been shown that the Cox proportional hazards model can be approximated with a
Poisson GLMM by splitting follow-up time tik (and event indicator yik) into j narrow time intervals of ﬁxed length
(L5d) (Crowther et al., 2012). The parameter λj then represents the baseline hazard rate during the j
th time interval,
and β is once again the log hazard ratio for the treatment effect. An additional advantage of this approach is that
the proportional hazards assumption can be relaxed, for example, by replacing the Poisson with a log-gamma
distribution or by pre-specifying the baseline function h0(t) in L5b (Barrett et al., 2012; Siannis et al., 2010).3.4.6. Other. Several one-stage models have been proposed for IPD-MA where the outcome belongs to another
type of non-normally distributed data (Thompson et al., 2001), recurrent events (Haines and Hill, 2011), repeated
measurements (Jones et al., 2009), or multivariate responses (Kim et al., 2013; Riley et al., 2008; Yamaguchi et al.,
2002).3.5. Meta-analysis of individual participant data combined with aggregate data
Subject-level data are often unavailable for all relevant studies (Ravva et al., 2014; Donegan et al., 2013; Saramago
et al., 2012; Jansen, 2012; Riley et al., 2008; Sutton et al., 2008; Riley et al., 2007). Therefore, published AD may
represent an additional source of evidence. Including published AD in an IPD-MA is strongly recommended when
studies providing IPD systematically differ from studies for which IPD were not obtained, as this may lead to data
availability bias or reviewer selection bias (Ahmed et al., 2012). But even when there is no indication of such bias,
inclusion of AD in an IPD-MA for studies of which IPD are lacking may be considered to increase the statistical
power for detecting treatment effects or treatment-covariate interactions (Donegan et al., 2013; Jansen, 2012;
Saramago et al., 2012). In general, there are three alternate approaches for combining IPD and AD in a meta-
analysis:
• Meta-analysis of AD
In this approach, the available IPD are ﬁrst reduced to AD (Ravva et al., 2014; Riley et al., 2007) and then pooled
into a weighted average as in two-stage meta-analysis. When investigating the presence of effect modiﬁcation,
caution is warranted to avoid the introduction of ecological bias (Signorovitch et al., 2012; Jackson et al., 2008;
Riley et al., 2008, 2007; Tudur Smith et al., 2005b; Wakeﬁeld and Salway, 2001).
• Meta-analysis of reconstructed IPD
It is possible to reconstruct IPD from published aggregate information for binary (based on 2 × 2 tables), ordinal
(based on the number of responses within each treatment category), and survival type data (based on Kaplan–
Meier survival curves) (Guyot et al., 2012; Riley and Steyerberg, 2010; Riley et al., 2007). In particular, this summary
information can be used to restore subject-level information on treatment group and outcome status (or time
until event). Afterwards, (traditional) one-stage models can be used for evidence synthesis. Unfortunately,
reconstructed IPD do not have subject-level information on covariates and may therefore lead to ecological bias
when investigating the presence of effect modiﬁcation.
• Hierarchical-related regression
This approach directly combines the likelihood from each data source (IPD or AD), for example, using Bernoulli
(IPD) and binomial (AD) distributions for modeling the individual responses and trial-speciﬁc summaries of binary
outcome data (Ravva et al., 2014; Saramago et al., 2012; Jansen, 2012; Sutton et al., 2008; Jackson et al., 2008, 2006;
Goldstein et al., 2002). In this manner, it ensures that all studies contribute toward estimation of the overall
treatment effect and study-level covariates and that only IPD are used to estimate subject-level covariate effects.
Hierarchical related regression is also known as shared parameters models (Donegan et al., 2013) and can, for
instance, be achieved by ﬁtting a multilevel model that includes a dummy variable indicating whether a data
source relates to IPD or AD (Riley et al., 2008, 2007; Goldstein et al., 2000).
Unfortunately, the incorporation of AD in an IPD-MA does not necessarily improve the validity of estimated
treatment effects and interactions. In particular, amongst other issues, the exclusion of subjects post
randomization (Tierney and Stewart, 2005) as well as the presence of limited follow-up data and informative
drop-out may introduce bias in published AD. Because researchers may often ﬁnd themselves between the Scylla
and Charybdis when deciding to include published AD in an IPD-MA, it has been recommended to assess the
sensitivity of meta-analysis results to the inclusion of AD (Riley and Steyerberg, 2010; Riley et al., 2008, 2007). This
can, for instance, be achieved by performing an IPD-only meta-analysis and meta-analysis that combines IPD and
AD. An additional advantage of sensitivity analyses is that they may help readers without (advanced) statistical
expertise to interpret results in function of the underlying assumptions.© 2015 The Authors. Research Synthesis Methods published by John Wiley & Sons, Ltd. Res. Syn. Meth. 2015, 6 293–309
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In a different article of this series, we discuss in depth the use of network meta-analysis (NMA) models for
synthesizing information from multiple treatments across different studies (Efthimiou et al., 2015). These models
allow the estimation of the relative treatment effect between many (rather than two) speciﬁc interventions, even
when these interventions have never been compared head-to-head. The implementation of NMA models is,
however, less straightforward than traditional meta-analysis models and requires studies to have similar covariate
distributions for important effect modiﬁers (Signorovitch et al., 2010). For this reason, it is important to correct for
baseline imbalance between studies (Ali et al., 2013; Jansen, 2012) and explore the presence of treatment-covariate
interactions (Donegan et al., 2012; Jansen, 2012; Signorovitch et al., 2012). This is ideally achieved using IPD.
The speciﬁcation of IPD-NMA models can be viewed as an extension of regression model (1) where a dummy
variable is included for each (except one) treatment (Higgins et al., 2001). It is, however, more common to describe
NMA models as a function of consistency equations, which simpliﬁes the speciﬁcation of interaction effects
(Donegan et al., 2013; Jansen, 2012; Saramago et al., 2012). The use of IPD in NMA has been advocated even if
IPD are only available for a fraction of the studies (Jansen, 2012). Recently, several NMA models have been
proposed that allow the combined use of IPD and AD in a joint analysis (Donegan et al., 2013; Jansen, 2012;
Saramago et al., 2012). These models were shown to have improved network consistency when compared to
NMA models that were solely based on AD. Similar to AD-NMA, the quality of evidence resulting from an
IPD-NMA strongly depends upon the quality and choice of included studies, the complexity and credibility of
statistical models, and the transparency of reporting. A questionnaire for assessing the relevance and credibility
of NMA studies has recently been reported by the International Society for Pharmacoeconomics and Outcomes
Research and may help to improve the quality of IPD-NMA studies (Jansen et al., 2014).3.7. Cross-design synthesis
Most trials are conducted to establish efﬁcacy and safety of a single treatment in a speciﬁc study setting, and
therefore it is often difﬁcult to translate this evidence to “real-world” effectiveness where different concerns
may be at play (Prevost et al., 2000; Stuart et al., 2011). For this reason, there is a growing interest to
overcome the weaknesses of individual study designs by carefully combining different types of evidence
(Droitcour et al., 1993). In particular, intervention research might beneﬁt by the inclusion of non-randomized
study data such as from (case-)cohort studies, case-control studies, or patient registries (Higgins et al., 2013;
Kaizar, 2011; Peters et al., 2005; Prevost et al., 2000; Li and Begg, 1994). This strategy is more commonly
known as cross-design synthesis or generalized synthesis of evidence (Sutton and Higgins, 2008; Sutton
et al., 1998).
Because non-randomized studies of interventions (NRSI) are inherently prone to confounding, there is
substantial controversy about the magnitude and interpretation of potential differences between the results from
RCTs and NRSI (Reeves et al., 2003; Valentine and Thompson, 2013; Schmidt et al., 2013; Golder et al., 2011;
Ioannidis et al., 2001; Concato et al., 2000). Whether or not it is valid to combine RCT and NRSI in IPD-MA and under
what conditions is an ongoing debate in the literature (Higgins et al., 2013; Reeves et al., 2003). So far, cross-design
synthesis has only been advocated when the likelihood of conducting randomized trials is low (e.g., due to ethical
concerns or practical limitations) or when research questions relate to unintended, rare (often harms), or long-
term outcomes (beneﬁts or harms). The justiﬁcation of including NRSI may further increase when the derived
estimates of relative treatment effects are deemed to be resistant against bias. This becomes more plausible when
there are no systematic differences between the groups being compared (e.g., in terms of care provided, exposure
to other factors, baseline characteristics, or in terms of how outcomes are determined).
To improve the validity of meta-analyses incorporating evidence resulting from NRSI, several suggestions have
been made. First, researchers should critically appraise the risk of bias in available studies prior to cross-design
synthesis and carefully decide whether inclusion is appropriate (Berger et al., 2014; Higgins et al., 2013; Reeves
et al., 2003; Wells et al., 2013). Subsequently, researchers should routinely account for confounding factors within
studies. Finally, researchers should explore potential sources of between-study heterogeneity and compare the
results between randomized studies and NRSI (Valentine and Thompson, 2013).3
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13.8. Dealing with missing data
Missing data are a common problem when analyzing IPD from any (single) study and are typically classiﬁed into
missing completely at random (MCAR), missing at random (MAR), and missing not at random (MNAR) (Rubin,
1987). These types correspond to situations where the probability of data being missing is completely
independent of observed and unobserved factors (MCAR), depends only on the observed data (MAR), or also
depends on unobserved data (MNAR) (Donders et al., 2006; Schafer, 1999; Rubin, 1987). When data are missing
within a single study, it is generally recommended to apply multiple imputation strategies by adopting a statistical
model that assumes MCAR or MNAR. We can distinguish the following missing data scenarios in an IPD-MA
(Sutton et al., 1998):© 2015 The Authors. Research Synthesis Methods published by John Wiley & Sons, Ltd. Res. Syn. Meth. 2015, 6 293–309
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2• missing data for some subjects in one or more studies,
• missing data for all subjects of one or more studies (e.g., variables that have not been measured, outcomes
that are missing, or missing study-level covariates), and
• entire study missing (e.g., when study authors are unable to share IPD).
Because the association between observed and missing variables may differ across studies, it has been
recommended to allow for between-study heterogeneity during imputation. This can, for instance, be achieved
by imputing IPD studies separately (two-stage imputation) (Burgess et al., 2013; Koopman et al., 2008a). Two-stage
imputation is obviously not feasible if data are missing for all subjects within one or more studies. In such
scenarios, it is desirable to use the so-called one-stage imputation models that borrow information across the
available studies (Jolani et al., 2015; Burgess et al., 2013; Resche-Rigon et al., 2013; White et al., 2008; Yucel,
2008, 2011).3.9. Software and estimation techniques for individual participant data meta-analysis
Several software packages exist for conducting an IPD-MA and adopt a frequentist or a Bayesian estimation
framework (Tables 2 and 3). Frequentist methods typically maximize the likelihood function of the meta-analysis
model using expectation–maximization (Vaida and Xu, 2000), Newton–Raphson, or Fisher scoring algorithms.
Unfortunately, maximization of the (log-)likelihood function becomes problematic when there are few studies
in the meta-analysis or included studies are small (Crowther et al., 2012; Li et al., 2011; Thompson et al., 2001;
Higgins et al., 2001). For this reason, it is often recommended to adopt more advanced estimation techniques such
as restricted (or residual) maximum likelihood estimation (Bowden et al., 2011; Higgins et al., 2001), penalized
maximum likelihood estimation (Rondeau et al., 2008), penalized quasi-likelihood (Thompson et al., 2001),
extended quasi-likelihood estimation, penalized partial likelihood estimation, or semi-parametric-penalizedTable 2. Software packages for ﬁtting meta-analysis models
Software Package Characteristics Used in
WinBUGS,
JAGS, Stan,
OpenBUGS
– Fitting of one-stage and two-stage meta-analysis
models using Bayesian Markov chain Monte Carlo
(MCMC)
[26, 32, 48, 52, 67, 81, 86,
95, 98, 118, 126, 146, 147]
NONNEM – Fitting of GLMM [87]
R, S-plus* – Unspeciﬁed [9, 103, 104]
– ecoreg Estimation of individual-level covariate-outcome
associations using AD (“ecological inference”) or a
combination of AD and individual participant data
(IPD) (“hierarchical-related regression”)
[52]
– glmmML Fitting of GLMM using ML. Allows for non-normal
distributions in the speciﬁcation of random
intercepts.
[11]
– hglm Fitting of GLMM where the random effect may come
from a conjugate exponential-family distribution
–
– lme4 Fitting of GLMM using ML or REML (for mixed linear
models only)
[11, 30, 56, 65, 110, 153],
SI3
– MASS Fitting of GLMM using penalized quasi-likelihood
(PQL)
–
– mvmeta Meta-analysis and meta-regression of AD (two-stage
meta-analysis)
[30], SI3
– nlme Fitting of linear mixed-effects models using ML or
REML
[89, 122]
– survival Fitting of Cox PH and mixed effect survival models
using penalized partial likelihood estimation (PPL)
[44, 122, 132, 133]
– frailtypack Fitting of frailty models using semi-parametric-
penalized likelihood (SPL)
[97]
– coxme Fitting mixed effects Cox PH models –
GLMM, generalized linear mixed model; AD, aggregate data; PH, proportional hazards; REML, restricted (or
residual) maximum likelihood; ML, maximum likelihood.
References are provided in Supporting Information (SI) 4.
*An overview of software packages for two-stage meta-analysis can be found on http://cran.r-project.org/web/
views/MetaAnalysis.html.
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Table 3. Software packages for ﬁtting meta-analysis models
Software Package Characteristics Used in
SAS – Unspeciﬁed [106, 122, 132,
133]
– PROC
GLIMMIX
Fitting of GLMM using penalized quasi-likelihood (PQL) [82, 129]
– PROC GLM Fitting of GLMM using MOM [148]
– PROC
LOGISTIC
Fitting of mixed nonlinear models (binary/ordinal/nominal
responses) using ML
[147]
– PROC
MIXED
Fitting of mixed linear models using ML, REML, or MOM. Can
also perform two-stage meta-analysis.
[48, 57, 93]
– PROC
NLMIXED
Fitting of mixed nonlinear models using (approximated) ML [95, 114, 148]
Stata – Unspeciﬁed [3, 4, 45]
– gllamm Fitting of GLMM using ML –
– mvmeta Meta-analysis and meta-regression of aggregate data (AD)
(two-stage meta-analysis)
[5]
– REGOPROB2 Fitting of random effects generalized-ordered probit models [26, 95, 122]
– stmixed Fitting of ﬂexible parametric survival models with mixed effects –
– XT Fitting of GLMM –
MLwiN,
MLn
– Fitting of GLMM and survival models using ML, REML, and EM [41, 48, 122, 126,
136, 147]
FORTRAN,
C
– Unspeciﬁed [60, 97, 137]
GLMM, generalized linear mixed model; REML, restricted (or residual) maximum likelihood; ML, maximum
likelihood; MOM, method of moments; EM, expectation maximization.
References are provided in Supporting Information 4.
T. P. A. DEBRAY ET AL.likelihood estimation. Unfortunately, these techniques are not widely implemented to investigate nonlinear
outcomes (e.g., binary, ordinal, or count data).
The Bayesian framework combines the likelihood function with prior information (Yamaguchi et al., 2002;
Higgins et al., 2001; Sargent, 1998; Larose and Dey, 1997) and is typically implemented within WinBUGS, JAGS,
OpenBUGS, or Stan. The use of prior information may help to overcome convergence issues when studies are
small or few studies are available (Table 4). Semi-informative prior distributions may, for instance, be used
when model parameters are unidentiﬁable due to a lack of data (Jackson et al., 2008). Alternatively, informative
prior distributions may be used, for example, when relevant information can be borrowed from historical dataTable 4. Overview of prior distributions used within the Bayesian framework
– Prior distribution 95% prior belief Used in
Parameters for ﬁxed effects (regression coefﬁcients)
Non-informative β ∼N(0, 106) [0.00; +∞) for the odds ratio [98, 118]
– β ∼N(0, 105) [0.00; +∞) for the odds ratio [26]
– β ∼N(0, 104) [0.00; +∞) for the odds ratio [32, 48, 70, 86, 95, 126, 147]
– β ∼N(0, 10) [0.00; 494] for the odds ratio [86]
Weakly informative β ∼N(0, 1.47) [0.20; 5.03] for the odds ratio [52]
Parameters for between-study standard deviation
Non-informative τ2 ∼Γ 1(10 3, 103) [1.2 × 107, +∞) for τ [67]
– τ2 ∼Γ 1(10 3, 10 3) [3.2 × 104; +∞) for τ [48, 81, 147]
– τ2 ∼U(0.01, 100) [1.62; 9.87] for τ [70]
– τ ∼N(0, 10)I(0) [0.30; 22.48] for τ [146]
– τ ∼U(0, 10) [0.25; 9.76] for τ [32, 118]
Weakly informative τ ∼U(0, 5) [0.12; 4.88] for τ [86]
– τ ∼U(0, 2) [0.05; 1.96] for τ [98]
– τ ∼N(0, 1)I(0) [0.03; 2.24] for τ [26, 95]
– τ ∼U(0, 1) [0.02; 0.98] for τ [126]
– τ ∼N(0, 0.125)I(0) [0.01; 0.80] for τ [86]
– τ2 ∼Γ 1(1, 10 2) [0.05; 0.62] for τ [52]
– τ ∼N(0, 0.033)I(0) [0.01; 0.41] for τ [86]
References are provided in Supporting Information 4.
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4(Viele et al., 2014). An additional advantage of the Bayesian framework is that it allows more ﬂexibility in
choosing and combining likelihood functions that are appropriate for the data that are being analyzed. As
such, the use of Bayesian meta-analyses may sometimes help to improve the credibility of estimated treatment
effects and between-study heterogeneity. The Bayesian framework, however, requires careful speciﬁcation of
prior distributions, investigation of convergence, and the drawing of inferences from a large simulated sample.
Because it tends to be cumbersome and requires substantial statistical expertise, Bayesian IPD-MA is not
pursued by many researchers.4. Concluding remarks
Individual participant data meta-analyses offer numerous advantages over meta-analyses that are solely based on
published AD and are therefore considered as a gold standard in evidence synthesis. Nevertheless, the presence
of publication bias, data accessibility bias, or reviewer selection bias may still hamper or invalidate the results of an
IPD-MA (Ahmed et al., 2012), and synchronizing between different sources of IPD is not always straightforward. For
this reason, it is not recommended to conduct IPD-MA on an ad hoc basis (e.g., without systematic review).
Because the implementation of an IPD-MA requires additional efforts and statistical expertise, researchers should
carefully assess whether the potential advantages (e.g., increased power, reduced bias, and investigating
interaction and subgroup effects) outweigh the extra efforts involved. Finally, researchers should be aware that
IPD-MA may have similar issues to meta-analyses of published AD and are no panacea against poorly designed
and conducted primary research.Acknowledgements
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